Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.IBM is contributing a huge database of chemical data extracted patents and scientific literature to the National Institutes of Health (NIH), as a step towards speed drug discovery and cancer research innovation.
Subscribe to our email newsletter
IBM has collaborated with AstraZeneca, Bristol-Myers Squibb, DuPont and Pfizer, to provide a database of over 2.4 million chemical compounds extracted from about 4.7 million patents and 11 million biomedical journal abstracts from 1976 to 2000.
IBM made use of its business analytics and optimization strategic IP insight platform (SIIP), a combination of data and analytics delivered via the IBM SmartCloud, to extract the data.
This cloud-driven method for curating and analyzing massive amounts of patents, scientific content and molecular data uses techniques such as automated image analysis and enhanced optical recognition of chemical images and symbols to extract information from patents and literature upon publication.
The publicly available chemical data is believed to help researchers worldwide to gain new insights and enable new areas of research, besides saving time by efficiently finding information stored in millions of pages of patent documents.